1,3-bis[12-hydroxy-octadecamide-N-methylene]-benzene

Acute Toxicity: dermal

Administrative data

Endpoint:

acute toxicity: dermal

Type of information:

migrated information: read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: see 'Remark'

Remarks:

Study data over 12 years old provided by ECHA, on a previously notified substance considered comparable and suitable for read-across use for the substance being registered (see attachments for justification of read-across). Study conducted in accordance with generally accepted scientific principles, possibly with incomplete or methodological deficiencies, which do not affect the quality of relevant results.

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2013

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

EU Method B.3 (Acute Toxicity (Dermal))

Deviations:

not specified

GLP compliance:

yes

Test type:

standard acute method

Limit test:

yes

Test material

Test material information

Constituent 1

Reference substance name:

-

EC Number:

423-300-7

EC Name:

-

Cas Number:

128554-52-9

Molecular formula:

Molecular formula varies for each reaction product. See section 1.2 for the molecular formula for each identified reaction product.

IUPAC Name:

12-hydroxy-N-({3-[(12-hydroxyoctadecanamido)methyl]phenyl}methyl)octadecanamide

Constituent 2

Reference substance name:

AMIDE#71

IUPAC Name:

AMIDE#71

Test material form:

solid: particulate/powder

Remarks:

migrated information: powder

Details on test material:

Identification: AMIDE#71

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

Wistar strain Crl:(WI) BR

Administration / exposure

Type of coverage:

semiocclusive

Vehicle:

corn oil

Duration of exposure:

24 hour

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

5 males and 5 females at 2000 mg/kg bw.

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days

Observations were made for mortality, signs of toxicity, and effects on organs at necropsy.

The test sites were examined for evidence of primary irritation and scored according to the Draize scale.

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

No mortality occurred at 2000 mg/kg.
Male: 2000 mg/kg bw; Number of animals: 5; number of deaths: 0
Female: 2000 mg/kg bw; Number of animals: 5; number of deaths: 0

Clinical signs:

other: Signs of toxicity related to dose levels: No abnormalities found.

Gross pathology:

Effects on organs: No abnormalities were found in the animals at macroscopic post mortem examination.

Other findings:

Signs of toxicity (local):
No clinical signs of local toxicity (irritation) were observed.

Applicant's summary and conclusion

Interpretation of results:

not classified

Remarks:

Migrated information Criteria used for interpretation of results: EU

Conclusions:

The acute dermal LD50 of the test material in the Wistar strain rats (male and female) was determined to be greater than 2000 mg/kg bodyweight.

Executive summary:

The test substance was assessed for acute dermal toxicity according to EU Method B3. 

No mortality occurred at 2000 mg/kg. There were no signs of toxicity related to dose levels during the 14 day observation period, and no abnormalities were found in the animals at macroscopic post mortem examination. 

The acute dermal LD50 of the test material in the Wistar strain rats (male and female) was determined to be greater than 2000 mg/kg bodyweight.